URIPAN XR 10 MG 30 TAB

49.50 EGP

Each extended release film coated tablet contains 10 mg of oxybutynin hydrochloride.

URIPAN XR 10 MG 30 TAB; oxybutynin, genitourinary agents .

ACTIVE-INGREDIENT OF URIPAN XR 10 MG 30 TAB

Each extended release film coated tablet contains 10 mg of oxybutynin hydrochloride.

INDICATION OF URIPAN XR 10 MG 30 TAB

Adults: Uripan XR is indicated in adults for the symptomatic treatment of urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with unstable bladder. Paediatric population: Uripan XR is indicated in children over 5 years of age for: Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity). Nocturnal enuresis associated with detrusor overactivity, in conjunction with nondrug therapy, when other treatment has failed.

DOSAGE OF URIPAN XR 10 MG 30 TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

Uripan XR may be administered with or without food. Adults: Starting dose: the recommended starting dose is one 5 mg tablet once daily. Maintenance dose/dose adjustment: In order to achieve a maintenance dose giving an optimal balance of efficacy and tolerability, after at least one week on 5 mg daily, the dose may be increased to 10 mg once daily, with subsequent incremental increases or decreases of 5 mg/day. There should be an interval of at least one week between dose changes. Maximum dose: in patients requiring a higher dose, the total daily dose should not exceed 20 mg. For patients currently taking oxybutynin immediate release, clinical judgement should be exercised in selecting the apprpriate dose of Uripan XR. The dosage should be adjusted to the minimum dose that achieves an optimal balance of efficacy and tolerability, taking into account the current immediate release dose. In case of a missed dose, the patient should wait and take the nest dose at the regular time. Elderly patients: No dosage adjustment is necessary in elderly patients. Children over the age of 5 years: Initial dose of 5 mg once a day increased in 5 mg increments up to a maximum of 15 mg once a day. Uripan XR is not recommended for use in children below age of 5 years, due to a lack of data on safety and efficacy. Method of administration: Uripan XR must be swallowed whole with the aid of liquid, and must not be chewed, divided, or crushed because the tablet is formulated to provide extended release. Patients should be advised that the tablet membrane may pass through the gastrointestinal tract unchanged, This has no bearing on the efficacy of the product.

OVER-DOSAGE OF URIPAN XR 10 MG 30 TAB

The symptoms of overdose with oxybutynin progress from an intensification of the usual side effects of CNS disturbances ( from restlessness and and excitement to psychotic behavior ) , circulatory changes ( flushing , fall in blood pressure, circulatory failure etc ) , respiratory failure , paralysis and coma measures to be taken are : 1 ) Administration of activated charcoal . 2 ) physostigmine by slow intravenous injection . Fever should be treated symtomatically with tepid sponging or ice packs . In pronounced restlessness or excitation , diazepam may be given by intravenous injection , tachycardia may be treated by intravenous injection of propranolol and urinary retention can be managed by catheterisation . In the event of progression of the curare – like effect to the paralysis of the respiratory muscles mechanical ventilation will be required . The continuous release of oxybutynin from Uripan XR should be considered in the treatment overdose. Patients should be monitored for at least 24 hours.

CONTRA-INDICATION OF URIPAN XR 10 MG 30 TAB

Hypersensitivity to the active substance or to any of the excipients. Narrow-angle glaucoma or shallow anterior chamber . Myasthenia gravis . Urinary retention. Gastrointestinal obstructive disorders including paralytic ileus or intestinal atony . Severe ulcerative colitis. Toxic megacolon . Urinary frequency and nocturia due to heart or renal failure. Porphyria.

STORAGE OF URIPAN XR 10 MG 30 TAB

Store at temperature not exceeding 30 ° C in dry place.
PACK OF URIPAN XR 10 MG 30 TAB
Carton box containing 2, 3 (AL/AL ) strips , each of 10 film coated tablets + insert leaflet .
URIPAN XR 10 MG 30 TAB MANUFACTURED BY
ADWIA Co. S.A.E. Tenth of Ramadan City Egypt.

https://www.drugs.com/oxybutynin.html

https://www.webmd.com/drugs/2/drug-1757-7152/oxybutynin-chloride-oral/oxybutynin-extended-release-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “URIPAN XR 10 MG 30 TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat